2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 353-355
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Microbiome, Diseases, Immunology, GVHD, Research, Fundamental Science, Translational Research, Study Population, Human, Animal Model
PAPER

122 Blood endothelial cells in secondary lymphoid organs prime alloreactive CD4⁺ T cells to initiate acute graft-versus-host disease

Muhammad Haroon Shaikh, PhD, Pia Wittmann2, Moutaz Helal, MSc3, Michael Kern4, Zahraa Abboud5, Hao Yan, PhD6, Angela Riedel7, Maike Büttner-Herold8, Hermann Einsele, MD, PhD9, Jochen Hühn10, Andreas Beilhack11
1 University Hospital Würzburg,, Würzburg, Germany
2 University Hospital Würzburg,, Würzburg, Germany
3 Mildred Scheel Early Career Centre, University Hospital Würzburg,, Würzburg, Germany
4 University Hospital Würzburg,, Würzburg, Germany
5 University Hospital Würzburg,, Würzburg, Germany
6 Stanford University, Palo Alto, California, United States
7 Mildred Scheel Early Career Centre, University Hospital Würzburg,, Würzburg, Germany
8 University Hospital Erlangen,, Erlangen, Germany
9 University Hospital Würzburg,, Würzburg, Germany, University Hospital Würzburg,, Würzburg, Germany
10 Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany
11 University Hospital Würzburg,, Würzburg, Germany

Allogeneic donor T cells mediate a curative graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation (allo-HCT) but also drive life-threatening acute graft-versus-host disease (aGvHD). Donor CD4? T-cell priming is a pivotal event determining allo-HCT outcome. Pathogenic donor CD4? T cells are activated through MHC class II (MHCII)-restricted antigen presentation, yet ablating MHCII on hematopoietic antigen-presenting cells (APCs) fails to prevent aGvHD (Toubai et al, Blood 2012; Koyama et al, Nat Med 2012), implicating non-hematopoietic APCs. Their identity and location remain controversial, with intestinal epithelial cells (IECs) proposed as peripheral initiators (Koyama et al, Immunity 2019). Because naïve donor CD4? T cells first traffic to secondary lymphoid organs (SLOs) to acquire tissue-homing receptors before infiltrating target tissues (Beilhack et al, Blood 2005, 2008), we reasoned that the initiating APC niche resides within SLOs and here identify SLO blood endothelial cells (BECs) as a non-hematopoietic APC population both necessary and sufficient to initiate aGvHD.

Using volumetric high-resolution 3D light-sheet fluorescence microscopy in a major MHC-mismatched model (FVB to C57BL/6), donor CD4? T cells were sequestered within SLOs during the first three days after allo-HCT, undergoing activation and clonal expansion, whereas the rare donor cells in the small intestine were strictly intravascular and not yet primed. Parenchymal infiltration occurred only from day 4 onward, and whole-tissue confocal and Swiss-roll imaging confirmed that extravascular donor T cells were absent from the lamina propria through day 3. Gut-homing receptor upregulation (α4β7, CCR9) required host MHCII, confirming that priming precedes and instructs migration. Interrogating scRNA-seq datasets of SLO stroma, we resolved arterial and venous BEC and lymphatic endothelial cell (LEC) subsets. Both constitutively expressed the antigen-processing and presentation machinery of professional APCs (Cd74, Ctsl, Ctss, H2-Aa, H2-Ab1, H2-Eb1) with CD80 and CD86, and efficiently processed DQ-OVA. After irradiation, BECs upregulated costimulatory ligands while maintaining MHCII, whereas LECs downregulated MHCII, revealing an intrinsic, radio-resistant antigen-presentation program unique to BECs.

To test necessity, we generated MHCIIΔCdh5 mice lacking MHCII on all endothelial cells. After allo-HCT, these recipients showed improved survival (52% vs. 20%) despite intact hematopoietic APCs, whereas LEC-specific deletion (MHCIIΔProx1) conferred no benefit, mapping endothelial APC function specifically to BECs. Consistent with this, BECs, but not LECs, expressed the peptide editor H2-M and a peptide-editing signature indicative of active MHCII loading. Mechanistically, conditioning induced an IL-12/IFNγ-dependent licensing program, irradiation triggered myeloid IL-12 and IFNγ production, driving BEC JAK-STAT activation and MHCII upregulation. Prophylactic IL-12p40 blockade suppressed donor CD4? T-cell expansion and improved survival (40% vs. 0%). To test sufficiency, we generated MHCIIΔVav1 mice, in which MHCII is restricted to the endothelium. SLO stromal cells and surgically engrafted MHCIIΔVav1 lymph nodes primed alloreactive CD4? T cells into polyfunctional TNFα?IFNγ? effectors in vivo, establishing that endothelial MHCII alone initiates disease independently of hematopoietic APCs.

Combined deletion of endothelial and hematopoietic MHCII (MHCIIΔVav1ΔCdh5) abolished donor T-cell TCR signaling and conferred near-complete protection (79% survival), whereas liver and lung endothelial cells could not prime CD4? T cells, demonstrating that this APC function is restricted to the lymphoid vascular niche. Critically, deleting endothelial MHCII remained protective even when IEC antigen presentation was preserved (83% vs. 36% survival), demonstrating that IECs are insufficient to initiate lethal alloimmunity without the SLO endothelial niche.

Collectively, these findings establish SLO BECs as initiators of alloreactive CD4? T-cell immunity and redefine the vascular-immune interface as a decisive checkpoint in aGvHD. Because the licensing IL-12/IFNγ axis is targetable with FDA-approved agents such as the anti-IL-12/23 p40 antibody ustekinumab, disrupting endothelial priming offers a rational strategy to uncouple aGvHD from the beneficial graft-versus-leukemia effect after allo-HCT.

Muhammad Haroon Shaikh, PhD: No relevant conflicts of interest to declare.